Sarcopenia Market Valued at USD 2.89 Bn in 2023, Expected to Reach USD 4.23 Bn by 2030 with a 5.6% CAGRSarcopenia Market Overview:
Sarcopenia is a condition where older people lose their muscle mass and strength as they age, causing problems like falling down, breaking bones, becoming disabled, and even death. Sarcopenia generally starts to happen in the 40s, and it continues to get worse as one gets older. By the time person reach the 80s,may have lost about half of muscle mass. Sarcopenia can be caused by things like getting older, not being active, having chronic diseases, or not eating well.Sarcopenia results in a bad quality of life as well as disability. Sarcopenia has no definitive cure, there are several treatments that slow down the disease and improve quality of life. Along with aging sarcopenia is also associated with several health problems such as Heart disease, Strokes, and cancer. Musculoskeletal conditions are increasing day by day worldwide. A recent publication by WHO states that 1.71 billion people have musculoskeletal conditions globally,driving the Sarcopenia market. Sarcopenia Market Scope and Research Methodology: The Sarcopenia Market report offers a brief overview of the global Sarcopenia market. The report insights into growth factors, limitations, and emerging market trends in the industry. The report provides a segmentation of the Sarcopenia market by treatment type, route of administration, distribution channel and end-user market, and region. Primary research includes interviews with market experts, clinicians, and patients, and secondary research involving data collected from publications, government websites, and other sources. The collected data was analysed using statistical tools such as descriptive statistics and forecasting models.The Sarcopenia Market report also provides information about the leading players in the market, their business overview, financial overview, and recent developments.To know about the Research Methodology :- Request Free Sample Report
Sarcopenia Market Dynamics:
Drivers: Rising Awareness of Sarcopenia Among Medical Professionals and The General Public Sarcopenia is a medical condition that is prevalent as the global population ages. By 2030, around 1 in 6 people in the world will be 60 years old or older, according to a recent report by the World Health Organization. Rising awareness of Sarcopenia among medical professionals and the general public is driving the market growth. People are becoming more aware of Sarcopenia and its symptoms, such as reduced muscle mass and strength, as well as decreased physical performance. Early diagnosis and treatment of Sarcopenia lead to improve quality of life and reduce the progression of the disease. Increased awareness is driving demand for Sarcopenia diagnostic procedures and treatments, thereby contributing to the growth of the market. Restraints: High Cost of Treatment is a Significant Barrier to Sarcopenia Market The high cost of treatment is a major challenge for patients, as protein supplements and resistance training, which are common therapies are expensive and unaffordable for those with limited financial means. The lack of appropriate curative therapy for sarcopenia hinders market growth, as there are currently no approved muscle-building agents available. Non-drug therapies like exercise and lifestyle modifications are the primary methods used, but they do not provide a complete solution. Diagnosing sarcopenia can be complex and require specialized tools that may not be widely accessible, leading to under diagnosis and delayed treatment. Treatment options, such as nutritional supplements and pharmacological interventions are costly, especially in the long term, posing a noteworthy restraint for individuals without adequate healthcare coverage. Regulatory hurdles in the development and approval of drugs targeted for sarcopenia can cause delays in market entry. The coexistence of sarcopenia with other age-related conditions also presents challenges in managing multiple conditions simultaneously. Lastly, limited scientific knowledge and ongoing research gaps impede the development of targeted interventions, impacting the market's growth.Sarcopenia Market Segment Analysis:
Based on treatment type,the protein supplements segment is expected to be the growing segment of the market. This is due to the increasing awareness of the importance of protein for muscle health.In addition to traditional protein supplements, there are also emerging therapies that utilize novel protein sources. For example, a new study published in April 2022 is investigating the role of Blue Whiting protein hydrolysates combined with physical exercise help to improve overall body lean mass and muscle strength in elderly free-living communities.Based on End-user market segmented into Hospitals are expected to drive the market due to the high prevalence of Sarcopenia among hospitalized patients. Many patients in hospitals, especially older individuals or those with underlying health conditions, experience muscle loss due to factors like extended bed rest or limited mobility. Hospitals have specialized departments and healthcare professionals experienced in dealing with geriatric conditions, offering comprehensive medical services, diagnostic tests, therapies, and surgeries if needed. Clinics, specializing in geriatric care or musculoskeletal health, are also significant in the Sarcopenia market. These clinics provide outpatient services, focusing on early detection, diagnosis, and treatment of Sarcopenia Healthcare settings beyond hospitals and clinics, such as rehabilitation centers, nursing homes, assisted living facilities, and home healthcare services, form another end-user segment. This segment is expected to grow rapidly, driven by the increasing number of individuals with Sarcopenia receiving treatment at home.
Sarcopenia Market Regional Insights:
North America is dominating the Sarcopenia market in 2023 and is expected to continue its dominance during the forecast period. This is mainly due to the high occurrence of Sarcopenia among the elderly population in the region, along with the increasing healthcare spending and the presence of key players in the market. North America benefits from advanced healthcare facilities and a growing awareness of the disease among healthcare professionals and patients. Asia-Pacific region is expected to have rapid growth in the Sarcopenia market. This can be attributed to the increasing number of elderly individuals, a rise in healthcare expenditure, and the presence of several pharmaceutical companies catering to market demands. Followed by Europe, the Middle East, and South America are also expected to experience substantial growth, with a fast Compound Annual Growth Rate (CAGR). This is primarily driven by the ageing population in these regions, which necessitates the development of solutions and treatments for Sarcopenia.Competitive Landscape for Sarcopenia Market:
The Sarcopenia Market is highly competitive and key companies are investing significant resources in research and development to create novel and innovative therapies. These companies are competing in terms of product quality, price, and innovation, driving the growth of the market. For instance, in 2022, Bayer AG introduced its novel concept of Healthy Aging, which has aimed the transforming ageing with health innovation.In addition to developing new drugs, companies are expanding their product through acquisitions and mergers. This led to the introduction of a number of new and innovative products in the market. Sanofi S.A., Glaxo Smith Kline plc., Novartis AG, Pfizer Inc., Asta Real AB, Merck Sharp & Dohme Corp., AbbVie Inc. and Amgen Inc. are some major key players in Sarcopenia market.Sarcopenia Market Scope: Inquire before buying
Global Sarcopenia Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 2.89 Bn. Forecast Period 2024 to 2030 CAGR: 5.6% Market Size in 2030: US $ 4.23 Bn. Segments Covered: by Treatment Type Protein Supplement Vitamin B12 Supplement Vitamin D & Calcium Supplement Exercise therapy Pharmacotherapy Others by Route of Administration Oral Parenteral Enteral by Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies Others by End-User Hospitals Clinics Homecare settings Sarcopenia Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Sarcopenia Market Key Players
1. Bayer AG 2. Zydus Cadila 3. GlaxoSmithKline plc 4. Nestle Health Science 5. Sanofi S.A. 6. GlaxoSmithKline plc. 7. Novartis AG 8. Pfizer Inc. 9. AstaReal AB 10. Merck Sharp & Dohme Corp. 11. AbbVie Inc. 12. Abbott laboratories, Inc. 13. American Way (Amway) Corporation 14. F-Hoffmann La-Roche 15. Amgen Inc. 16. Johnson & Johnson FAQs: 1. What is the growth rate of the Sarcopenia Market? Ans. Sarcopenia Market is expected to grow by 5.6%. 2. What segments are covered in the Sarcopenia Market report? Ans. The segments covered are treatment type, Route of Administration, Distribution channel, End-users and region. 3. What are the key driving factors for the growth of the Sarcopenia Market? Ans. Increasing healthcare expenditures and the growing geriatric population will likely accelerate the growth of the Sarcopenia Market. 4. Which segments dominate the Sarcopenia market growth? Ans. Treatment dominates the Sarcopenia Market Growth over the forecast period. 5. Which region has the largest share in Sarcopenia Market? Ans. North America holds the highest share in 2023.
1. Sarcopenia Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Sarcopenia Market: Dynamics 2.1. Sarcopenia Market Trends by Region 2.1.1. North America Sarcopenia Market Trends 2.1.2. Europe Sarcopenia Market Trends 2.1.3. Asia Pacific Sarcopenia Market Trends 2.1.4. Middle East and Africa Sarcopenia Market Trends 2.1.5. South America Sarcopenia Market Trends 2.2. Sarcopenia Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Sarcopenia Market Drivers 2.2.1.2. North America Sarcopenia Market Restraints 2.2.1.3. North America Sarcopenia Market Opportunities 2.2.1.4. North America Sarcopenia Market Challenges 2.2.2. Europe 2.2.2.1. Europe Sarcopenia Market Drivers 2.2.2.2. Europe Sarcopenia Market Restraints 2.2.2.3. Europe Sarcopenia Market Opportunities 2.2.2.4. Europe Sarcopenia Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Sarcopenia Market Drivers 2.2.3.2. Asia Pacific Sarcopenia Market Restraints 2.2.3.3. Asia Pacific Sarcopenia Market Opportunities 2.2.3.4. Asia Pacific Sarcopenia Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Sarcopenia Market Drivers 2.2.4.2. Middle East and Africa Sarcopenia Market Restraints 2.2.4.3. Middle East and Africa Sarcopenia Market Opportunities 2.2.4.4. Middle East and Africa Sarcopenia Market Challenges 2.2.5. South America 2.2.5.1. South America Sarcopenia Market Drivers 2.2.5.2. South America Sarcopenia Market Restraints 2.2.5.3. South America Sarcopenia Market Opportunities 2.2.5.4. South America Sarcopenia Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Sarcopenia Industry 2.8. Analysis of Government Schemes and Initiatives For Sarcopenia Industry 2.9. Sarcopenia Market Trade Analysis 2.10. The Global Pandemic Impact on Sarcopenia Market 3. Sarcopenia Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 3.1.1. Protein Supplement 3.1.2. Vitamin B12 Supplement 3.1.3. Vitamin D & Calcium Supplement 3.1.4. Exercise therapy 3.1.5. Pharmacotherapy 3.1.6. Others 3.2. Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 3.2.1. Oral 3.2.2. Parenteral 3.2.3. Enteral 3.3. Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 3.3.1. Hospital Pharmacies 3.3.2. Retail Pharmacies 3.3.3. Online Pharmacies 3.3.4. Others 3.4. Sarcopenia Market Size and Forecast, by End-User (2023-2030) 3.4.1. Hospitals 3.4.2. Clinics 3.4.3. Homecare settings 3.5. Sarcopenia Market Size and Forecast, by Region (2023-2030) 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 4. North America Sarcopenia Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 4.1.1. Protein Supplement 4.1.2. Vitamin B12 Supplement 4.1.3. Vitamin D & Calcium Supplement 4.1.4. Exercise therapy 4.1.5. Pharmacotherapy 4.1.6. Others 4.2. North America Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 4.2.1. Oral 4.2.2. Parenteral 4.2.3. Enteral 4.3. North America Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 4.3.1. Hospital Pharmacies 4.3.2. Retail Pharmacies 4.3.3. Online Pharmacies 4.3.4. Others 4.4. North America Sarcopenia Market Size and Forecast, by End-User (2023-2030) 4.4.1. Hospitals 4.4.2. Clinics 4.4.3. Homecare settings 4.5. North America Sarcopenia Market Size and Forecast, by Country (2023-2030) 4.5.1. United States 4.5.1.1. United States Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 4.5.1.1.1. Protein Supplement 4.5.1.1.2. Vitamin B12 Supplement 4.5.1.1.3. Vitamin D & Calcium Supplement 4.5.1.1.4. Exercise therapy 4.5.1.1.5. Pharmacotherapy 4.5.1.1.6. Others 4.5.1.2. United States Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 4.5.1.2.1. Oral 4.5.1.2.2. Parenteral 4.5.1.2.3. Enteral 4.5.1.3. United States Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 4.5.1.3.1. Hospital Pharmacies 4.5.1.3.2. Retail Pharmacies 4.5.1.3.3. Online Pharmacies 4.5.1.3.4. Others 4.5.1.4. United States Sarcopenia Market Size and Forecast, by End-User (2023-2030) 4.5.1.4.1. Hospitals 4.5.1.4.2. Clinics 4.5.1.4.3. Homecare settings 4.5.2. Canada 4.5.2.1. Canada Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 4.5.2.1.1. Protein Supplement 4.5.2.1.2. Vitamin B12 Supplement 4.5.2.1.3. Vitamin D & Calcium Supplement 4.5.2.1.4. Exercise therapy 4.5.2.1.5. Pharmacotherapy 4.5.2.1.6. Others 4.5.2.2. Canada Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 4.5.2.2.1. Oral 4.5.2.2.2. Parenteral 4.5.2.2.3. Enteral 4.5.2.3. Canada Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 4.5.2.3.1. Hospital Pharmacies 4.5.2.3.2. Retail Pharmacies 4.5.2.3.3. Online Pharmacies 4.5.2.3.4. Others 4.5.2.4. Canada Sarcopenia Market Size and Forecast, by End-User (2023-2030) 4.5.2.4.1. Hospitals 4.5.2.4.2. Clinics 4.5.2.4.3. Homecare settings 4.5.3. Mexico 4.5.3.1. Mexico Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 4.5.3.1.1. Protein Supplement 4.5.3.1.2. Vitamin B12 Supplement 4.5.3.1.3. Vitamin D & Calcium Supplement 4.5.3.1.4. Exercise therapy 4.5.3.1.5. Pharmacotherapy 4.5.3.1.6. Others 4.5.3.2. Mexico Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 4.5.3.2.1. Oral 4.5.3.2.2. Parenteral 4.5.3.2.3. Enteral 4.5.3.3. Mexico Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 4.5.3.3.1. Hospital Pharmacies 4.5.3.3.2. Retail Pharmacies 4.5.3.3.3. Online Pharmacies 4.5.3.3.4. Others 4.5.3.4. Mexico Sarcopenia Market Size and Forecast, by End-User (2023-2030) 4.5.3.4.1. Hospitals 4.5.3.4.2. Clinics 4.5.3.4.3. Homecare settings 5. Europe Sarcopenia Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.1. Europe Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.1. Europe Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.1. Europe Sarcopenia Market Size and Forecast, by End-User (2023-2030) 5.5. Europe Sarcopenia Market Size and Forecast, by Country (2023-2030) 5.5.1. United Kingdom 5.5.1.1. United Kingdom Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.5.1.2. United Kingdom Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.5.1.3. United Kingdom Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.1.4. United Kingdom Sarcopenia Market Size and Forecast, by End-User (2023-2030) 5.5.2. France 5.5.2.1. France Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.5.2.2. France Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.5.2.3. France Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.2.4. France Sarcopenia Market Size and Forecast, by End-User (2023-2030) 5.5.3. Germany 5.5.3.1. Germany Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.5.3.2. Germany Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.5.3.3. Germany Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.3.4. Germany Sarcopenia Market Size and Forecast, by End-User (2023-2030) 5.5.4. Italy 5.5.4.1. Italy Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.5.4.2. Italy Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.5.4.3. Italy Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.4.4. Italy Sarcopenia Market Size and Forecast, by End-User (2023-2030) 5.5.5. Spain 5.5.5.1. Spain Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.5.5.2. Spain Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.5.5.3. Spain Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.5.4. Spain Sarcopenia Market Size and Forecast, by End-User (2023-2030) 5.5.6. Sweden 5.5.6.1. Sweden Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.5.6.2. Sweden Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.5.6.3. Sweden Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.6.4. Sweden Sarcopenia Market Size and Forecast, by End-User (2023-2030) 5.5.7. Austria 5.5.7.1. Austria Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.5.7.2. Austria Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.5.7.3. Austria Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.7.4. Austria Sarcopenia Market Size and Forecast, by End-User (2023-2030) 5.5.8. Rest of Europe 5.5.8.1. Rest of Europe Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 5.5.8.2. Rest of Europe Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 5.5.8.3. Rest of Europe Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.8.4. Rest of Europe Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6. Asia Pacific Sarcopenia Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.2. Asia Pacific Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.3. Asia Pacific Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.4. Asia Pacific Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5. Asia Pacific Sarcopenia Market Size and Forecast, by Country (2023-2030) 6.5.1. China 6.5.1.1. China Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.1.2. China Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.1.3. China Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.1.4. China Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.2. S Korea 6.5.2.1. S Korea Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.2.2. S Korea Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.2.3. S Korea Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.2.4. S Korea Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.3. Japan 6.5.3.1. Japan Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.3.2. Japan Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.3.3. Japan Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.3.4. Japan Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.4. India 6.5.4.1. India Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.4.2. India Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.4.3. India Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.4.4. India Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.5. Australia 6.5.5.1. Australia Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.5.2. Australia Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.5.3. Australia Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.5.4. Australia Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.6. Indonesia 6.5.6.1. Indonesia Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.6.2. Indonesia Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.6.3. Indonesia Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.6.4. Indonesia Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.7. Malaysia 6.5.7.1. Malaysia Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.7.2. Malaysia Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.7.3. Malaysia Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.7.4. Malaysia Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.8. Vietnam 6.5.8.1. Vietnam Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.8.2. Vietnam Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.8.3. Vietnam Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.8.4. Vietnam Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.9. Taiwan 6.5.9.1. Taiwan Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.9.2. Taiwan Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.9.3. Taiwan Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.9.4. Taiwan Sarcopenia Market Size and Forecast, by End-User (2023-2030) 6.5.10. Rest of Asia Pacific 6.5.10.1. Rest of Asia Pacific Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 6.5.10.2. Rest of Asia Pacific Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 6.5.10.3. Rest of Asia Pacific Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.10.4. Rest of Asia Pacific Sarcopenia Market Size and Forecast, by End-User (2023-2030) 7. Middle East and Africa Sarcopenia Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 7.2. Middle East and Africa Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 7.3. Middle East and Africa Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 7.4. Middle East and Africa Sarcopenia Market Size and Forecast, by End-User (2023-2030) 7.5. Middle East and Africa Sarcopenia Market Size and Forecast, by Country (2023-2030) 7.5.1. South Africa 7.5.1.1. South Africa Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 7.5.1.2. South Africa Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 7.5.1.3. South Africa Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 7.5.1.4. South Africa Sarcopenia Market Size and Forecast, by End-User (2023-2030) 7.5.2. GCC 7.5.2.1. GCC Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 7.5.2.2. GCC Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 7.5.2.3. GCC Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 7.5.2.4. GCC Sarcopenia Market Size and Forecast, by End-User (2023-2030) 7.5.3. Nigeria 7.5.3.1. Nigeria Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 7.5.3.2. Nigeria Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 7.5.3.3. Nigeria Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 7.5.3.4. Nigeria Sarcopenia Market Size and Forecast, by End-User (2023-2030) 7.5.4. Rest of ME&A 7.5.4.1. Rest of ME&A Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 7.5.4.2. Rest of ME&A Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 7.5.4.3. Rest of ME&A Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 7.5.4.4. Rest of ME&A Sarcopenia Market Size and Forecast, by End-User (2023-2030) 8. South America Sarcopenia Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 8.2. South America Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 8.3. South America Sarcopenia Market Size and Forecast, by Distribution Channel(2023-2030) 8.4. South America Sarcopenia Market Size and Forecast, by End-User (2023-2030) 8.5. South America Sarcopenia Market Size and Forecast, by Country (2023-2030) 8.5.1. Brazil 8.5.1.1. Brazil Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 8.5.1.2. Brazil Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 8.5.1.3. Brazil Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 8.5.1.4. Brazil Sarcopenia Market Size and Forecast, by End-User (2023-2030) 8.5.2. Argentina 8.5.2.1. Argentina Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 8.5.2.2. Argentina Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 8.5.2.3. Argentina Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 8.5.2.4. Argentina Sarcopenia Market Size and Forecast, by End-User (2023-2030) 8.5.3. Rest Of South America 8.5.3.1. Rest Of South America Sarcopenia Market Size and Forecast, by Treatment Type (2023-2030) 8.5.3.2. Rest Of South America Sarcopenia Market Size and Forecast, by Route of Administration (2023-2030) 8.5.3.3. Rest Of South America Sarcopenia Market Size and Forecast, by Distribution Channel (2023-2030) 8.5.3.4. Rest Of South America Sarcopenia Market Size and Forecast, by End-User (2023-2030) 9. Global Sarcopenia Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2023) 9.3.5. Company Locations 9.4. Leading Sarcopenia Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Bayer AG 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Zydus Cadila 10.3. GlaxoSmithKline plc 10.4. Nestle Health Science 10.5. Sanofi S.A. 10.6. GlaxoSmithKline plc. 10.7. Novartis AG 10.8. Pfizer Inc. 10.9. AstaReal AB 10.10. Merck Sharp & Dohme Corp. 10.11. AbbVie Inc. 10.12. Abbott laboratories, Inc. 10.13. American Way (Amway) Corporation 10.14. F-Hoffmann La-Roche 10.15. Amgen Inc. 10.16. Johnson & Johnson 11. Key Findings 12. Industry Recommendations 13. Sarcopenia Market: Research Methodology 14. Terms and Glossary